What it's for (Indications)
- This medication is indicated for the management of hypertension, for treating edema associated with heart disease, and for the management of Nephrotic Syndrome.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of hydrochlorothiazide and valsartan must be individualized based on the patient's blood pressure response and tolerability. It is typically administered orally once daily, with or without food. For patients whose blood pressure is not adequately controlled with monotherapy of either valsartan or hydrochlorothiazide, combination therapy may be initiated. The usual starting dose for valsartan/hydrochlorothiazide combination can range from 80 mg valsartan / 12.5 mg hydrochlorothiazide to 160 mg valsartan / 12.5 mg hydrochlorothiazide once daily. The dose can be titrated upwards after 1 to 2 weeks of therapy based on blood pressure response, with common maintenance doses including 160 mg/12.5 mg, 320 mg/12.5 mg, or 320 mg/25 mg daily. The maximum recommended dose is typically 320 mg valsartan / 25 mg hydrochlorothiazide once daily. Dose adjustments are generally not required for patients with mild to moderate renal impairment (creatinine clearance ≥30 mL/min). However, this combination is contraindicated in patients with anuria, and caution is advised in severe renal impairment (creatinine clearance <30 mL/min) due to the hydrochlorothiazide component. Similarly, caution is warranted in patients with mild to moderate hepatic impairment, and it is generally not recommended in severe hepatic impairment. Monitoring of electrolytes, renal function, and blood pressure is crucial during dose titration and maintenance therapy to ensure optimal efficacy and safety. The lowest effective dose should always be sought. |
Safety & Warnings
Common Side Effects
- The co-administration of hydrochlorothiazide and valsartan is generally well-tolerated, but like all medications, it can cause various side effects.
- Common side effects reported include dizziness, headache, fatigue, nasopharyngitis, upper respiratory tract infection, cough, diarrhea, nausea, and back pain.
- These are often mild and transient.
- More serious, albeit less common, side effects warranting medical attention include symptomatic hypotension (especially in volume-depleted patients), syncope, and orthostatic hypotension.
- Electrolyte imbalances are a significant concern due to the hydrochlorothiazide component, potentially leading to hypokalemia, hyponatremia, hypomagnesemia, and hypercalcemia.
- Conversely, valsartan can cause hyperkalemia, particularly in patients with renal impairment, diabetes, or those concurrently taking potassium-sparing diuretics or potassium supplements, though the combination often mitigates these opposing effects.
- Renal dysfunction, including acute renal failure, can occur, particularly in patients with pre-existing renal impairment or severe heart failure.
- Other potential adverse events linked to hydrochlorothiazide include hyperglycemia, hyperuricemia (which can precipitate gout attacks), pancreatitis, and rare dermatological reactions like photosensitivity or skin rash.
- Valsartan, being an angiotensin receptor blocker, carries a small risk of angioedema, manifesting as swelling of the face, lips, tongue, or throat, which requires immediate medical intervention.
- Regular monitoring of blood pressure, electrolytes, and renal function is recommended during therapy to detect and manage potential adverse effects proactively.
Serious Warnings
- Black Box Warning: Valsartan, a component of this medication, can cause injury and even death to the developing fetus when used during the second and third trimesters of pregnancy. When pregnancy is detected, valsartan/hydrochlorothiazide should be discontinued as soon as possible. Drugs that act directly on the renin-angiotensin system (RAS), including valsartan, can cause fetal and neonatal morbidity and death when administered to pregnant women. Exposure to angiotensin receptor blockers (ARBs) during the second and third trimesters is known to induce fetotoxicity in humans, characterized by decreased renal function, oligohydramnios, skeletal malformations, and lung hypoplasia. Neonatal adverse effects may include skull hypoplasia, anuria, hypotension, and renal failure, leading to death. While the risk of adverse outcomes appears to be lower with exposure during the first trimester, it cannot be entirely excluded. For patients planning pregnancy, alternative antihypertensive therapies with a better established safety profile for use in pregnancy should be considered. If a patient becomes pregnant while taking this medication, it must be discontinued immediately, and the patient should be apprised of the potential hazard to the fetus. Consideration should also be given to appropriate fetal monitoring to assess for potential fetal injury. These serious risks underscore the critical importance of avoiding valsartan/hydrochlorothiazide during pregnancy.
- Patients should exercise caution when driving or operating machinery as this medication may affect their abilities.
- Alcohol consumption should be avoided.
- Caution is advised in patients suffering from gout, diabetes, and those with moderate to high cholesterol concentrations.
How it Works (Mechanism of Action)
Hydrochlorothiazide and valsartan is a combination antihypertensive agent that leverages two distinct pharmacological mechanisms to achieve blood pressure reduction. Valsartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, primarily located in vascular smooth muscle and the adrenal gland. By blocking the AT1 receptor, valsartan prevents the vasoconstrictor and aldosterone-secreting effects of angiotensin II, leading to vasodilation, a decrease in systemic vascular resistance, and a reduction in blood pressure. This blockade also results in a decrease in sodium and water retention. Hydrochlorothiazide is a thiazide diuretic that acts primarily in the cortical diluting segment of the distal convoluted tubule of the kidney. It inhibits the sodium-chloride cotransporter, thereby decreasing the reabsorption of sodium and chloride ions. This increased excretion of sodium, chloride, and accompanying water leads to a reduction in plasma volume, cardiac output, and consequently, blood pressure. Additionally, hydrochlorothiazide also increases the excretion of potassium and bicarbonate and decreases the excretion of calcium. The combination of valsartan and hydrochlorothiazide offers an additive antihypertensive effect. Valsartan counteracts the sympathetic nervous system activation and renin-angiotensin-aldosterone system stimulation that can be induced by diuresis, and it helps to mitigate the potassium-losing effect of hydrochlorothiazide. This synergistic action leads to a more pronounced and sustained reduction in blood pressure compared to either agent used alone, while also improving tolerability.